IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 1376.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 8-Jul-2015
Nanomedicine
UK study reveals new method to develop more efficient drugs
A new study led by University of Kentucky researchers suggests a new approach to develop highly potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.

Contact: Allison Perry
allison.perry@uky.edu
859-323-2399
University of Kentucky

Public Release: 8-Jul-2015
PLOS ONE
Study estimates number of deaths attributed to low levels of education
A new study by researchers at the University of Colorado, New York University, and the University of North Carolina at Chapel Hill estimates the number of deaths that can be linked to differences in education, and finds that variation in the risk of death across education levels has widened considerably.
NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development

Contact: Rachel Harrison
rachel.harrison@nyu.edu
212-998-6797
New York University

Public Release: 8-Jul-2015
Oncogene
Disrupting cells' 'powerhouses' can lead to tumor growth, Penn study finds
A study by University of Pennsylvania researchers implicates defects in mitochondria, the energy-production centers of cells, as playing a key role in the transition from normal to cancerous.
National Institutes of Health, Harriet Ellison Woodward Trust

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Public Release: 8-Jul-2015
Proceedings of the National Academy of Sciences
Hybrid cells cause chaos around cancers
Rice University researchers have built a simulation to understand how cancerous tumors manipulate blood-vessel growth.
National Science Foundation, Cancer Prevention and Research Institute of Texas, São Paulo Research Foundation, Tauber Family Funds, Maguy-Glass Chair in Physics of Complex Systems at Tel Aviv University

Contact: David Ruth
david@rice.edu
713-348-6327
Rice University

Public Release: 8-Jul-2015
Nature
Treating breast cancer with progesterone could aid survival
A special technique where breast cancer cells are 'rescued' for research has been developed at the University of Adelaide. Coupled with advanced scientific technologies pioneered by Cambridge University this has provided a unique insight into the hormone regulation of breast cancers, which is expected to lead to new treatments for the disease.
Cancer Research UK, European Research Council, National Health and Medical Research Council of Australia, Cancer Australia, National Breast Cancer Foundation

Contact: Wayne Tilley
wayne.tilley@adelaide.edu.au
61-041-780-7895
University of Adelaide

Public Release: 8-Jul-2015
Journal of Hepatology
Research links intrahepatic cholestasis of pregnancy with liver cancer and other diseases later in life
In a new study of more than 125,000 pregnant women in Sweden, researchers found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy than in women without this condition. Their results are published in the Journal of Hepatology.

Contact: Sybrand Boer Iwema
hmsmedia@elsevier.com
31-204-852-781
Elsevier Health Sciences

Public Release: 8-Jul-2015
Nature
Common hormone could help treat breast cancer
Around half of all breast cancer patients could one day benefit from having the cheap and widely-available female hormone progesterone added to their treatment, according to Cancer Research UK funded research published in Nature.
Cancer Research UK

Contact: Ailsa Stevens
ailsa.stevens@cancer.org.uk
44-203-469-8300
Cancer Research UK

Public Release: 8-Jul-2015
European Journal of Immunology
Lymphoma: How the tumor escapes the immune response
Natural killer cells of the immune system can fend off malignant lymphoma cells and thus are considered a promising therapeutic approach. However, in the direct vicinity of the tumor they lose their effect. Scientists of Helmholtz Zentrum München have now elucidated which mechanisms block the natural killer cells and how this blockade could be lifted. The results were recently published in the European Journal of Immunology.
Wilhelm Sander-Stiftung

Contact: Dr. Ralph Mocikat
Mocikat@helmholtz-muenchen.de
49-893-187-1302
Helmholtz Zentrum München - German Research Center for Environmental Health

Public Release: 7-Jul-2015
Journal of the Royal Society of Medicine
Mammography benefits overestimated
An in-depth review of randomized trials on screening for breast, colorectal, cervical, prostate and lung cancers, published in the Journal of the Royal Society of Medicine, shows that the benefits of mammographic screening are likely to have been overestimated.

Contact: Jenny Gimpel
jenny.gimpel@kcl.ac.uk
44-207-848-4334
King's College London

Public Release: 7-Jul-2015
Chemical Science
Sensor technology can improve accuracy of prostate cancer diagnosis, research shows
New research has shown how a smart sensor chip, able to pick up on subtle differences in glycoprotein molecules, can improve the accuracy and efficiency of prostate cancer diagnosis.

Contact: Luke Harrison
l.harrison.1@bham.ac.uk
University of Birmingham

Public Release: 7-Jul-2015
JAMA
Findings suggest improvement in management of localized prostate cancer
After years of overtreatment for patients with low-risk prostate cancer, rates of active surveillance/ watchful waiting increased sharply in 2010 through 2013, and high-risk disease was more often treated appropriately with potentially curative local treatment rather than androgen deprivation alone, according to a study in the July 7 issue of JAMA.

Contact: Elizabeth Fernandez
Elizabeth.Fernandez@UCSF.edu
415-514-1592
The JAMA Network Journals

Public Release: 7-Jul-2015
Technology
Microfabricated device allows evaluation of the efficacy, toxicity of pro-drugs
A team of researchers from the MGH Center for Engineering in Medicine has developed a novel approach that dramatically simplifies the evaluation of the liver's drug-metabolizing activity and the potential toxic effects of the products of that activity on other organs.

Contact: Philly Lim
mllim@wspc.com.sg
65-646-65775
World Scientific

Public Release: 7-Jul-2015
JAMA
Association between genetic condition, hormonal factors, and risk of endometrial cancer
For women with Lynch syndrome, an association was found between the risk of endometrial cancer and the age of first menstrual cycle, having given birth, and hormonal contraceptive use, according to a study in the July 7 issue of JAMA. Lynch syndrome is a genetic condition that increases the risk for various cancers.

Contact: Aung Ko Win, M.B.B.S., Ph.D., M.P.H.
awin@unimelb.edu.au
The JAMA Network Journals

Public Release: 7-Jul-2015
Cell Reports
Two are better than one -- another checkpoint enzyme for flawless cell division
The error-free distribution of genetic material during cell division is important for preventing the development of tumor cells. Professor Erich Nigg's research group at the Biozentrum, University of Basel, has uncovered a new important function of the human enzyme Plk1. It plays a significant role in monitoring chromosome segregation. The results published in the journal Cell Reports may provide important clues for the treatment of cancer.

Contact: Olivia Poisson
olivia.poisson@unibas.ch
University of Basel

Public Release: 7-Jul-2015
Proceedings of the National Academy of Sciences
Cancer drug 49 times more potent than Cisplatin
Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin. Based on a compound of the rare precious metal osmium and developed by researchers at the University of Warwick's Department of Chemistry and the Warwick Cancer Research Unit, FY26 is able to shut down a cancer cell by exploiting weaknesses inherent in their energy generation.
Biotechnology and Biological Sciences Research Council, European Research Council, Wellcome Trust, European Union

Contact: Tom Frew
a.t.frew@warwick.ac.uk
44-247-657-5910
University of Warwick

Public Release: 7-Jul-2015
Practical Radiation Oncology
Extended-field IMRT does not increase duodenal toxicity risk
A study of women with cervical or endometrial cancer who require treatment to the para-aortic (PA) lymph nodes can safely receive extended-field intensity modulated radiation therapy without increased risk of duodenal toxicity, according to a study published in the July-August 2015 issue of Practical Radiation Oncology, the American Society for Radiation Oncology's journal focused on the clinical practice of radiation oncology.

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 7-Jul-2015
Oncogene
USC cancer researchers ID potential treatment for deadly lymphoma
New research from the USC Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.
National Institutes of Health, Southern California Clinical and Translational Science Institute, Stop Cancer Foundation

Contact: Alison Trinidad
alison.trinidad@usc.edu
323-442-3941
University of Southern California - Health Sciences

Public Release: 7-Jul-2015
Journal of Immunotherapy
Investigators develop activated T cell therapy for advanced melanoma
T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine. Published in the July/August issue of Journal of Immunotherapy, these new findings demonstrate that T cells derived from lymph nodes of patients with melanoma can be expanded in number and activated in the laboratory for intravenous administration in the treatment of patients.

Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Case Medical Center

Public Release: 6-Jul-2015
Thyroid
Pitt scientists lead consensus guidelines for thyroid cancer molecular tests
University of Pittsburgh Cancer Institute scientists recently led a panel of experts in revising national guidelines for thyroid cancer testing to reflect newly available tests that better incorporate personalized medicine into diagnosing the condition. Their clinical explanation for when to use and how to interpret thyroid cancer tests is published in the July issue of the scientific journal Thyroid.

Contact: Allison Hydzik
HydzikAM@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 6-Jul-2015
Oncotarget
Discovered a potential treatment option for children with Ewing's sarcoma
A research consortium made up of the Virgen del Rocio hospital in Seville, Sant Joan de Deu and the Bellvitge Biomedical Research Institute in Barcelona, has found a new therapeutic alternative for children who suffer from a malignant pediatric tumor bone and soft tissue called Ewing's sarcoma.

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 6-Jul-2015
Molecular and Cellular Biology
Protein implicated in osteosarcoma's spread acts as air traffic controller
The investigation of a simple protein has uncovered its uniquely complicated role in the spread of the childhood cancer, osteosarcoma. It turns out the protein, called ezrin, acts like an air traffic controller, coordinating multiple functions within a cancer cell and allowing it to endure stress conditions encountered during metastasis.
US Department of Defense

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 6-Jul-2015
CA: A Cancer Journal for Clinicians
Simply observing men with very low- and low-risk prostate cancer very effective and underused
Monitoring men with very low- and low-risk prostate cancers using watchful waiting or active surveillance, called expectant management, is a useful approach for a large number of men with localized tumors and could spare them the debilitating side effects of aggressive treatments.
American Cancer Society

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-794-2262
University of California - Los Angeles Health Sciences

Public Release: 6-Jul-2015
Cell Death & Disease
Aspirin may delay growth of asbestos-related cancer
A University of Hawai'i Cancer Center study finds aspirin may help mesothelioma patients.

Contact: Nana Ohkawa
nohkawa@cc.hawaii.edu
808-564-5911
University of Hawaii Cancer Center

Public Release: 6-Jul-2015
Proceedings of the National Academy of Sciences
Epigenetic driver of glioblastoma provides new therapeutic target
Using human tumor samples and mouse models, researchers at University of California, San Diego School of Medicine and Moores Cancer Center discovered that cancer stem cell properties are determined by epigenetic changes -- chemical modifications cells use to control which genes are turned on or off.
Sontag Foundation, Burroughs Wellcome Foundation, Kimmel Foundation, Doris Duke Foundation and Forbeck Foundation

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 6-Jul-2015
Experimental Dermatology
Non-invasive technique may help detect skin and other cancers
Researchers have developed a non-invasive technique that allows clinicians to accurately detect various forms of skin cancer.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Showing releases 151-175 out of 1376.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

  Search News Releases

     

 

EurekAlert!